

Todos Medical Ltd.

11:45 18 Nov 2020

Todos Medical reports positive initial proof-of-concept data for its rapid COVID-19 test

Todos Medical Ltd (OTCQB:TOMDF) Wednesday announced what it called "positive clinical proof of concept data" from its lab-based rapid SARS-CoV-2 3CL protease diagnostic test in collaboration with its joint venture partner NLC Pharma.

The company said the data, which was generated by NLC Pharma in Israel, produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples.

Todos Medical Chief Medical & Scientific Officer Jorge Leon said in a statement: "We believe that our rapid testing 3CL technology will successfully pair with the antigen testing distribution networks being established to bring the point-of-care version of our 3CL assay into the market for widespread uptake as the long-term solution for rapid point of care COVID testing. In the meantime, we will deploy our clinical lab-based 3CL assay together with our existing PCR testing distribution networks to confirm that positive PCR tests are, in fact, picking up actively replicating virus versus inactive viral remnants that can sometimes show false positive RT-PCR results, keeping the person in quarantine needlessly. This would be quite an important addition to the current emerging COVID-19 testing paradigm."

READ: Todos Medical says it expects COVID-19 testing sales to drive business in the near term

Todos Medical noted that its team is now gathering additional clinical data to submit an emergency use authorization (EUA) to the United States Food & Drug Administration (FDA) for its lab-based test to be distributed through the company's existing lab distribution channels. Todos added that it is evaluating the best option for the commercialization of its rapid point-of-care version of the 3CL protease assay for the screening and diagnosis of symptomatic and asymptomatic COVID-19 carriers, based on recent updated guidance from the FDA for COVID-19 diagnostic point of care tests.


Todos Medical CEO Gerald Commissiong said in a recent update to shareholders that it is "squarely focused" on COVID-19 for the immediate term and expects revenues generated from sales of its COVID-19 testing solutions to be a near-term driver of business, this while continuing "to capitalize on the very significant programs we have in cancer and Alzheimer's diagnostics."

Contact Sean at sean@proactiveinvestors.com

Price: 0.0679

Market Cap: \$13.71 m

1 Year Share Price Graph



Share Information

Code: TOMDF

Listing: OTCQB

52 week High Low
0.1815 0.0111

Sector: Medical technology & services

Website: todosmedical.com

Company Synopsis:

Todos Medical Ltd. (OTCQB: TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic ("IVD") company developing a series of blood tests for the early detection of a variety of cancers. Our new cancer tests will add a layer to currently available cancer screening and diagnostics. Our goal is to help save lives through early detection while being minimally invasive to the patient.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).